Pharmacological activation of normal and arrhythmia-associated mutant KCNQ1 potassium channels

Circ Res. 2003 Nov 14;93(10):941-7. doi: 10.1161/01.RES.0000102866.67863.2B. Epub 2003 Oct 23.

Abstract

KCNQ1 alpha-subunits coassemble with KCNE1 beta-subunits to form channels that conduct the slow delayed rectifier K+ current (IKs) important for repolarization of the cardiac action potential. Mutations in KCNQ1 reduce IKs and cause long-QT syndrome, a disorder of ventricular repolarization that predisposes affected individuals to arrhythmia and sudden death. Current therapy for long-QT syndrome is inadequate. R-L3 is a benzodiazepine that activates IKs and has the potential to provide gene-specific therapy. In the present study, we characterize the molecular determinants of R-L3 interaction with KCNQ1 channels, use computer modeling to propose a mechanism for drug-induced changes in channel gating, and determine its effect on several long-QT syndrome-associated mutant KCNQ1 channels heterologously expressed in Xenopus oocytes. Scanning mutagenesis combined with voltage-clamp analysis indicated that R-L3 interacts with specific residues located in the 5th and 6th transmembrane domains of KCNQ1 subunits. Most KCNQ1 mutant channels responded to R-L3 similarly to wild-type channels, but one mutant channel (G306R) was insensitive to R-L3 possibly because it disrupted a key component of the drug-binding site.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Amino Acid Substitution
  • Animals
  • Anti-Arrhythmia Agents / pharmacology*
  • Arrhythmias, Cardiac / genetics*
  • Benzodiazepines / pharmacology
  • Binding Sites / genetics
  • Binding Sites / physiology
  • Humans
  • Ion Channel Gating / drug effects
  • KCNQ Potassium Channels
  • KCNQ1 Potassium Channel
  • Long QT Syndrome / genetics
  • Microinjections
  • Mutagenesis, Site-Directed
  • Mutation*
  • Oocytes / drug effects
  • Oocytes / metabolism
  • Patch-Clamp Techniques
  • Potassium Channels / drug effects*
  • Potassium Channels / genetics*
  • Potassium Channels / metabolism
  • Potassium Channels, Voltage-Gated*
  • Protein Structure, Tertiary / genetics
  • Protein Structure, Tertiary / physiology
  • Protein Subunits / drug effects
  • Protein Subunits / genetics
  • Protein Subunits / metabolism
  • Xenopus

Substances

  • Anti-Arrhythmia Agents
  • KCNQ Potassium Channels
  • KCNQ1 Potassium Channel
  • KCNQ1 protein, human
  • L 364373
  • Potassium Channels
  • Potassium Channels, Voltage-Gated
  • Protein Subunits
  • Benzodiazepines